Dianthus Therapeutics officer proposes $10.7M sale

The notice links the proposed sale to stock-option exercises over the next three months and lists August 7, 2026, as the Rule 10b5-1 plan adoption or instruction date.

Available on EDGAR 11/09/2026 - 04:37 PM EST Accepted by SEC EDGAR 11/09/2026 - 04:36 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Dianthus Therapeutics, Inc. officer Ryan Savitz filed a notice covering the proposed sale of 124,042 common shares, with an aggregate market value of $10,671,333.26. The notice lists Morgan Stanley Smith Barney LLC as broker and says the shares were and will be received through stock-option exercises over the next three months. It gives November 9, 2026, as the approximate sale date and August 7, 2026, as the date of plan adoption or instruction for Rule 10b5-1 reliance.

Key Figures

Shares proposed to be sold: 124,042 common shares Aggregate market value: $10,671,333.26 Shares outstanding: 56,312,712 shares +1 more

4 metrics

Shares proposed to be sold 124,042 common shares Ryan Savitz's notice

Aggregate market value $10,671,333.26 Shares listed for sale

Shares outstanding 56,312,712 shares Number listed in the notice

Approximate sale date November 9, 2026 Date listed in the notice

Key Terms

Rule 10b5-1, Exercise of Stock Options, Aggregate Market Value

3 terms

Rule 10b5-1 regulatory

"Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

Exercise of Stock Options financial

"Nature of Acquisition Transaction: Exercise of Stock Options"

Aggregate Market Value financial

"Number of Shares or Other Units To Be Sold | Aggregate Market Value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many DNTH shares did officer Ryan Savitz propose to sell?

Ryan Savitz's notice lists 124,042 common shares for sale, with an aggregate market value of $10,671,333.26 and an approximate sale date of November 9, 2026.

Was Ryan Savitz's proposed DNTH sale tied to a Rule 10b5-1 plan?

The notice lists August 7, 2026, as the date of plan adoption or giving of instruction for Rule 10b5-1 reliance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001992324
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Dianthus Therapeutics, Inc.
SEC File Number	001-38541
Address of Issuer	7 Times Square, 43rd Floor New York NEW YORK 10036
Phone	9299994055
Name of Person for Whose Account the Securities are To Be Sold	RYAN SAVITZ
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	124042	10671333.26	56312712	11/09/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/09/2026	Exercise of Stock Options	Issuer			124042	11/09/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.
Date of Notice	11/09/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/07/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Ryan Savitz
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)